Fathimanoud, Correspondent, India Pharma Outlook
Parameter | What to verify |
GMP | Current GMP certification/inspection status |
Cleanrooms | Grade A/B/C/D configuration |
Filling | Vial, ampoule, PFS, cartridge |
Technology | Isolator/RABS/closed processing |
Lyophilization | Number and scale of lyophilizers |
Sterilization | Terminal sterilization/aseptic processing |
QC | Analytical + microbiology capabilities |
Validation | Process/cleaning/aseptic validation |
Media fill | Frequency and qualification |
Technology transfer | Development-to-commercial pathway |
Regulatory | US/EU/other market experience |
Capacity | Current and future manufacturing slots |
Supply chain | API/component sourcing resilience |
Documentation | Batch records, CoA, stability, regulatory package |
India has moved beyond a low-cost manufacturing destination to become a strategic sterile injectable CDMO hub. Global sponsors now look to Indian partners for complex injectables, biologics, multi-format fill-finish, lyophilization and end-to-end regulatory support. Success depends on more than capacity.
Companies that select CDMOs with proven regulatory track records, modern barrier technologies, strong sterility assurance systems and clear clinical-to-commercial pathways will secure reliable supply and long-term partnership value.
The 2026 opportunity lies with partners that combine technical depth, Schedule M and global compliance, and the ability to scale complex sterile products for worldwide markets.
What should you check before choosing a sterile injectable CDMO in India?
Check regulatory inspection history, isolator or RABS capability, lyophilization capacity, container formats, analytical support, technology transfer process, global market experience, and available capacity.
What are the Grade A and Grade B requirements for sterile injectable manufacturing in India?
Grade A is the high-risk filling zone under ISO 5 with unidirectional airflow, while Grade B is the background environment for aseptic preparation and filling, meeting ISO 5 at rest and ISO 7 in operation.
What is the difference between aseptic fill-finish and terminal sterilization for injectables?
Aseptic fill-finish sterilizes the product and container separately, then assembles them under Grade A or B conditions, while terminal sterilization applies a final sterilization step after the product is filled and sealed.
Do Indian sterile injectable CDMOs support lyophilized injectable manufacturing?
Yes, many Indian sterile injectable CDMOs offer lyophilization for moisture-sensitive and unstable formulations at both clinical and commercial scale.
Can Indian sterile injectable CDMOs manufacture products for US FDA and European markets?
Yes, leading Indian sterile injectable CDMOs hold US FDA, EMA, and other international approvals and successfully supply regulated markets.
Fathimanoud is a Correspondent with experience covering the manufacturing and pharmaceutical sectors. She has written several articles on the pharma and manufacturing industries, with a particular focus on pharmaceutical developments and industry updates.
.jpg)
, CDSCO.jpg "Fostering a Quality Culture in the Pharmaceutical Industry")